Nicotinic acetylcholine receptor (nAChR) (nAChR)

The nicotinic acetylcholine receptor (nAChR) is a pentameric ligand-gated ion channel that mediates fast excitatory neurotransmission in both the central and peripheral nervous systems (StatPearls, 2023). These receptors are composed of various combinations of alpha, beta, gamma, delta, and epsilon subunits, which form a central aqueous pore that becomes permeable to cations like sodium and potassium upon binding the neurotransmitter acetylcholine (UniProt, 2024). In the periphery, muscle-type nAChRs are located at the neuromuscular junction and are essential for muscle contraction, while neuronal-type nAChRs in the brain modulate the release of other neurotransmitters such as dopamine and GABA (PubMed, 2021). Pathologically, nAChRs are central to Myasthenia Gravis, an autoimmune disorder where antibodies target the receptor, and they play significant roles in nicotine addiction and neurodegenerative diseases like Alzheimer's (NCBI, 2023). Therapeutic strategies involve a range of molecules, including agonists for smoking cessation, antagonists for surgical muscle relaxation, and positive allosteric modulators for cognitive enhancement (DrugBank, 2024). Due to their diverse subunit compositions and widespread physiological roles, nAChRs remain a critical target for developing subtype-specific drugs to treat neurological and neuromuscular disorders.

Other names

Cholinergic receptor nicotinicNicotinic receptornAChRIonotropic acetylcholine receptor

Drugs targeting nicotinic acetylcholine receptors act as agonists to open the ion channel and allow cation influx, antagonists to block the receptor and prevent neurotransmission, or allosteric modulators to tune receptor sensitivity (StatPearls, 2023; DrugBank, 2024).